Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$672.00K$672.00Kderived+190.9% vs Q4 2024 Net Income$1.39M$1.39MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$13,504,000N/M Operating Cash Flowderived-$14,764,000N/M Free Cash Flowderived-$15,669,000N/M Margins · derivedOperating margin-2009.5%+5998.7 pt vs Q4 2024
Net margin206.5%+12424.3 pt vs Q4 2024
ended Dec 31, 2025 · filed Apr 15, 2026 · 105 d after period end